Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagraxofusp + Low-Intensity Chemo in R/R ALL
NCT05032183Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2022
- Primary completion
- Jul 2024
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of tagraxofusp in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2022; status: terminated.
02
Drugs
tagraxofusp
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT05032183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05032183.